New study aims to help women stick with Life-Saving breast cancer treatment

NCT ID NCT07071038

Recruiting now Symptom relief Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

About half of women stop taking aromatase inhibitors early due to side effects, raising the risk of cancer returning. This study tests whether switching to a different hormone drug or using other symptom-relief methods works better at managing those side effects. Researchers will track symptom burden in 62 women with early breast cancer over 6 months to find the best approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anastrozole, exemestane, or tamoxifen
What this could lead to: If successful, this could provide a better way to manage side effects so more women complete their 5-year breast cancer treatment, reducing the risk of cancer returning.
What could go wrong: This is a small Phase 2 study with only 62 participants, so results may not apply to everyone. Side effects may still persist despite switching or other interventions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT TREATMENT BREAST CANCER EARLY-STAGE BREAST CANCER

Contacts and locations

Locations

Dartmouth Cancer Center
RECRUITING

Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.